What happened

Shares of Co-Diagnostics (NASDAQ:CODX) were soaring 15.5% higher as of 11:22 a.m. EDT on Thursday. The big jump came after the company announced that its COVID-19 test technology has been validated for use on saliva samples.

So what

Anyone who saw President Trump's press conference around a month ago after he was tested for COVID-19 heard the president say "there was nothing pleasant" about the test. Initial COVID-19 testing was done using nasal swabs. And they're not pleasant.

COVID-19 printed in white and red against a blue background.

Image source: Getty Images.

But COVID-19 tests that use saliva samples are much more pleasant. For those tests, individuals need only "swish and gargle," Co-Diagnostics CEO Dwight Egan said.

OraolDNA Labs' validation of Co-Diagnostics' COVID-19 test with saline oral rinse samples is good news for the company. OralDNA Labs also informed the U.S. Food and Drug Administration (FDA) that it plans to use Co-Diagnostics' validated test in its lab.

Co-Diagnostics' Logix Smart COVID-19 test is currently available for use in all labs certified under Clinical Laboratory Improvement Amendments (CLIA) under the FDA's Emergency Use Authorization program.

Now what

The COVID-19 outbreak has been a major catalyst for Co-Diagnostics, with its shares skyrocketing more than 1,100% so far this year. However, the company isn't profitable yet. The stock is now trading at an astronomically high price-to-sales multiple. Co-Diagnostics' revenue is likely to grow tremendously, but it remains to be seen if that growth will be enough to justify the stock's steep valuation.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.